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ABSTRACT
Angiotensin (Ang) II, the main effector peptide of the renin-angiotensin system, has 
been implicated in multiple aspects of cancer progression such as proliferation, migration, 
invasion, angiogenesis and metastasis. Ang-(1-7), is a biologically active heptapeptide, 
generated predominantly from AngII by the enzymatic activity of angiotensin converting 
enzyme 2. Previous studies have shown that Ang-(1-7) counterbalances AngII actions in 
different pathophysiological settings. In this study, we have analysed the impact of Ang-
(1-7) on AngII-induced pro-tumorigenic features on normal murine mammary epithelial 
cells NMuMG and breast cancer cells MDA-MB-231. AngII stimulated the activation of 
the survival factor AKT in NMuMG cells mainly through the AT1 receptor. This PI3K/AKT 
pathway activation also promoted epithelial–mesenchymal transition (EMT). Concomitant 
treatment of NMuMG cells with AngII and Ang-(1-7) completely abolished EMT features 
induced by AngII. Furthermore, Ang-(1-7) abrogated AngII induced migration and invasion 
of the MDA-MB-231 cells as well as pro-angiogenic events such as the stimulation of MMP-9 
activity and VEGF expression. Together, these results demonstrate for the first time that 
Ang-(1-7) counteracts tumor aggressive signals stimulated by AngII in breast cancer 
cells emerging the peptide as a potential therapy to prevent breast cancer progression.
INTRODUCTION
Independently of its role in homeostasis of cardiovascular 
and renal systems, angiotensin II (AngII) acts as a true 
cytokine modulating in a paracrine and autocrine manner 
multiple biological processes like tissue regeneration, cellular 
proliferation, growth factor release, and inflammation [1–3]. 
AngII acts through two different G protein-coupled receptors, 
AngII type 1 receptor (AT1) and AngII type 2 receptor (AT2), 
which have distinctive pharmacological and signal transducing 
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characteristics [4]. AT1 receptor mediates most of the AngII 
actions, thus representing a critical pharmacological target in the 
treatment of several cardiovascular disorders [5, 6].
In addition to AngII, the main effector peptide 
of the system, other peptides like AngIII [Ang-(2-8)], 
AngIV [Ang-(3-8)] and Ang-(1-7) have been identified 
as biologically active mediators of the renin-angiotensin 
system (RAS). In contrast to Ang metabolites with 
truncation on the N-terminus (AngIII and AngIV), which 
still show similar detrimental effects as Ang II due to 
stimulation of the AT1 receptor, the heptapeptide Ang-
(1-7) mainly generated by the monocarboxypeptidase 
angiotensin converting enzyme 2 (ACE 2), attracted 
special attention over the last two decades for showing 
the critical ability to counteract many actions of 
AngII in different pathophysiological settings [7–11]. 
Consequently, Ang-(1-7) has shown potent vasodilative, 
antiproliferative, antiangiogenic and antithrombotic 
properties [12–14]. We have previously identified the G 
protein–coupled receptor Mas, encoded by the Mas proto-
oncogene, as a receptor being associated with Ang-(1-7)-
mediated signaling [15]. Tissue RAS, where angiotensin 
peptides are locally produced in different organs have 
received special attention during the last decades [16]. 
Expression of RAS components such as angiotensinogen, 
renin, angiotensin converting enzyme, and angiotensin 
receptors in normal and transformed mammary ducts has 
been independently demonstrated by different groups [17–
20]. Moreover, we described a substantial contribution of 
the RAS in the postlactational regression phase, where 
AT1 receptor signaling together with other local factors 
mediates apoptosis and tissue remodeling in the mammary 
gland [20].
It has been demonstrated that AngII plays a critical 
role in breast cancer development by stimulating cell 
proliferation of breast cancer cells and tumor angiogenesis 
[21–23], and modulating tumor cell migration and invasion 
[24–28]. In addition, it has been recently demonstrated 
that overexpression of AT1 receptor in breast cancer cells, 
induces epithelial–mesenchymal transition (EMT) and 
promotes tumor growth and angiogenesis [29]. EMT is 
a highly conserved biological process characterized by 
the conversion of polarized, immotile epithelial cells into 
mesenchymal cells with a motile phenotype. It has been 
shown that EMT is involved in promoting cancer cell 
invasion, metastasis and chemoresistance [30]. Moreover, 
AT1 blockers (ARBs) or ACE inhibitors have efficiently 
reduced tumor growth, angiogenesis, and metastasis in 
experimental mouse models [31–34]. However, whether 
other angiotensin peptides can modulate AngII pro-
tumorigenic actions in mammary cells remain largely 
unknown. In the present work, we studied the impact of 
Ang-(1-7) on AngII-induced pro-oncogenic features in 
non-tumorigenic epithelial cells and breast cancer cells.
Here, we describe that AngII induced EMT in 
normal mammary epithelial cells is completely abolished 
by Ang-(1-7). Since migration and invasion features 
triggered by AngII in breast cancer cells are also blunted 
by the heptapeptide, it identifies Ang-(1-7) as a potential 
preventive therapy for breast cancer metastasis.
RESULTS
Ang-(1-7) inhibits ERK1/2 and AKT activation 
induced by AngII
Alterations on PI3K/AKT pathway have been shown 
to play a significant role in the development, progression, 
and metastatic spread of breast cancer cells. It has been 
shown that AngII induces AKT activation in several cell 
types [27, 28, 35].
In order to study the effects of AngII and Ang-(1-7) 
on AKT phosphorylation, the non-tumorigenic mammary 
epithelial cell line NMuMG was stimulated with AngII or 
Ang-(1-7) at 10-7 M for the indicated time (Figure 1A). AngII 
induced AKT phosphorylation that peaked at 1 min and 
declined to normal at 30 min. In contrast, Ang-(1-7) induced a 
maximal AKT phosphorylation at 15 min (Figure 1A). When 
both peptides were added together, maximal phosphorylation 
of AKT was observed at 15 minutes, resembling the pattern of 
activation induced by Ang-(1-7) and disappearing the peack 
observed at 1 min with AngII alone. We next determined 
ERK1/2 phosphorylation under angiotensin stimulation 
(Figure 1B). While AngII strongly induced ERK1/2 
activation with maximal activation at 5 min, a weaker, but 
significant signal was observed after Ang-(1-7) stimulation. 
Notably, this signal occurred earlier than the peak in AKT 
phosphorylation. When cells were simultaneously stimulated 
with both peptides, Ang-(1-7) significantly inhibited AngII 
induced ERK1/2 activation.
With the aim of identifying the receptor involved in 
AngII and Ang-(1-7) signal transduction, AKT or EKR1/2 
phosphorylation were determined in the presence of specific 
pharmacological receptors blockers targeting the RAS 
(Figure 2). AngII alone significantly induced AKT and 
ERK1/2 activation compared to control levels after 1min 
or 5min of incubation, respectively (Figure 2A&2C). In 
the presence of AT2 receptor blocker PD123319, AngII 
maintained significant levels of both AKT and ERK1/2 
activation with only a mild blockade observed. Both AKT 
and EKR1/2 activation induced by AngII were significantly 
blocked by an AT1 receptor blocker, Irbesartan, which 
restored values to control levels, suggesting that AngII 
exerts its function mainly through the AT1 receptor. In 
the presence of Ang-(1-7), AKT and ERK1/2 activation 
were induced (Figure 2A&2C). Similar levels of AKT and 
ERK1/2 activation induced by Ang-(1-7) were maintained in 
the presence of PD123319 or Irbesartan (data not shown) or 
the Ang-(1-7) antagonist D-Pro (D-Pro7-Ang-(1-7)), which 
has been identified as a Mas and MrgD receptor blocker in 
in vitro experiments [36, 37] (Figure 2B&2D). In contrast, 
treatment with the Mas receptor blocker, A779, significantly 
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blocked AKT and EKR1/2 phosphorylation induced by 
Ang-(1-7) to control levels (Figure 2B&2D). Notably, 
ERK1/2 phosphorylation, but not AKT phosphorylation, 
was significantly induced with PD123319 and D-Pro alone. 
Thus, we cannot conclude on PD and D-Pro effects of 
ERK1/2 activation since the compounds stimulates ERK1/2 
phosphorylation almost equally effective as Ang-(1-7) 
discarding significant blocking effects observed when Ang-
(1-7) and D-Pro were added together (Figure 2D).
Ang–(1-7) abolishes AngII induced epithelial-to-
mesenchymal transition
Reports strongly indicate that both invasion and 
metastasis may be dependent on the acquisition of 
epithelial-to-mesenchymal transition (EMT) features by 
primary cancer cells [38]. During EMT, cells lose their 
epithelial characteristics such as cell polarity and cell-cell 
contact, usually measured as a decrease in E-cadherin 
expression, and acquires mesenchymal features such 
as motility and a spindle-shaped phenotype [39, 40]. 
These attributes increase cell motility, resulting in the 
release of cells from the parental epithelial tissue site 
and gain the ability to reconstitute metastatic colonies 
at distant sites. A small subpopulation of cancer cells 
acquires cancer stem-like cell (CSCs) traits, exhibiting 
mesenchymal cell features associated with increase of 
EMT-related markers such us N-cadherin, Vimentin, 
α-SMA (anti alfa-smooth muscle actin), fibronectin or 
Snail [41]. The non-tumorigenic mammary epithelial 
Figure 1: Ang-(1-7) prevents AngII-induced AKT and ERK1/2 phosphorylation in the non-tumorigenic mammary cell 
line NMuMG. Left panels show representative Western blots; right panels show quantification by densitometry. Effect of AngII (10-7M) 
and/or Ang-(1-7) (10-7M) on AKT (A) and ERK1/2 (B) phosphorylation for the indicated time. WB analyses were performed using phospho-
specific antibodies against ERK1/2 and AKT. The same samples were blotted with antibodies to account for total kinase expression (lower 
panel for each kinase). N of 3 independent experiments; Values shown in bar represent mean± SEM, **P<0.01, ***P<0.001 vs untreated 
cells, ### P<0.001 vs AngII.
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cell line NMuMG is a generally accepted cell model to 
study EMT phenomena [42]. We describe here for the 
first time that treatment of NMuMG cells with AngII 
for 3 days resulted in a transition from an epithelial to 
a mesenchymal phenotype (Figure 3A). In the presence 
of AngII, the expression of epithelial markers such as 
E-cadherin was inhibited (0.52 fold vs control) while 
mesenchymal markers such as fibronectin, N-cadherin 
and α -SMA were enhanced (fibronectin 2.49 fold, 
N-cadherin 1.86 fold, and α–SMA 2.0 fold) (Figure 
3A). In contrast, Ang-(1-7) was unable to induce any 
changes on the expression of EMT markers. Importantly, 
when both peptides were simultaneously added to the 
cell culture, Ang-(1-7) abolished AngII-induced EMT 
changes in E-cadherin and fibronectin and partially 
blocked the changes in N-cadherin and α–SMA (Figure 
3A). Similar results and morphological changes were 
observed when immunofluorescence was performed to 
evaluate EMT markers on these cells (Figure 3B), with 
Ang-(1-7) preventing not only suppression of E-cadherin 
but also upregulation of fibronectin stimulated by AngII.
AngII induces EMT and migration through AKT 
activation
We further examined whether AKT activation is 
involved in AngII-induced EMT in mammary epithelial 
cells. We found that in the presence of the an AKT1/2 
kinase inhibitor, A6730, the expression of the epithelial 
and mesenchymal EMT biomarkers were almost restored 
to control levels, with highest efficacy on E-cadherin and 
fibronectin expression (Figure 4). These results suggest 
that AKT phosphorylation is at least in part necessary for 
AngII-induced EMT.
Ang-(1-7) prevents AngII-induced metastatic 
features on breast cancer cells
We next evaluated the effects of AngII and Ang-
(1-7) on cell migration and invasion in two potentially 
metastatic mammary cancer cells lines: MDA-MB-231 
(human) and LM3 (mouse). We found that Ang-(1-7) 
completely blocked AngII-induced tumor cell migration 
Figure 2: AngII induces ERK1/2 and AKT activation through AT1 receptor while Ang-(1-7) acts through the Mas 
receptor. Western Blot analyses from the non-tumorigenic mammary cell line NMuMG were performed for p-AKT and AKT (A-B) and 
p-ERK1/2 and ERK1/2 (C-D). Cells were pre-incubated for 5 min with Irbesartan (10-6 M), PD123319 (10-6 M), A779 (10-6 M), or D-Pro 
(10-6 M), and then stimulated with AngII (10-7M) (A-C) or (B-D) Ang-(1-7) (10-7M) for the indicated time. Blots show representative 
Western blots. N of 3 independent experiments; values shown in bar represent mean±SEM quantified by densitometry and relative to 
control-untreated cells. *P<0.05, **P<0.01, ***P<0.001 vs untreated control cells; # P<0.05, ##P<0.01, ### P<0.001 vs AngII or §§P<0.01, 
§§§P<0.001 vs Ang-(1-7) treated cells.
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Figure 3: Ang-(1-7) abolish AngII-induced EMT in the non-tumorigenic mammary cell line NMuMG. (A) Cells were 
treated with AngII (10-7M) and/or Ang-(1-7) (10-7M) for 3 days. The mRNA levels of E-cadherin, fibronectin, N-cadherin and ɑ-SMA 
were determined by qRT-PCR. mRNA levels have been normalized to GAPDH and relative to control. Bars indicate means ± SEM, n ≥ 
3, ***P<0.001 vs control, ###P<0.001 vs AngII, §P<0.05, §§P<0.01 vs Ang-(1-7) treated cells. (B) Upper Panel: influence of AngII (10-7M) 
and/or Ang-(1-7) (10-7M) on E-cadherin and fibronectin expression and subcellular localization after 3 days of treatments. NMuMG cells 
were immunostained for E-Cadherin (red) or fibronectin (green). Images are shown at ×400 magnification. Lower Panel: Bright fields of 
morphological changes induced by AngII (10-7M) on NMuMG treated cells during EMT process.
Figure 4: AngII induces EMT and through AKT activation. NMuMG cells were treated for 3 days with AngII (10-7M) in the presence or 
absence of an AKT inhibitor A6730 (1uM). The mRNA levels of E-Cadherin, Fibronectin, N-cadherin and ɑ-SMA were determined by qRT-PCR. mRNA 
levels have been normalized to GPDH and relative to control. Bars indicate means ± SEM, n ≥ 3, *P<0.05, **P<0.01, ***P<0.001 vs untreated cells.
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either performed on wound healing or in transwell assays 
(Figure 5A-5B). The migration observed was not due to 
proliferation, since neither AngII (10-7M) nor Ang-(1-7) 
(10-7M) did induce cell proliferation after 24h of treatment 
(Figure 5C).
Similar results were obtained in invasion assays using 
filters coated with matrigel that mimics the extracellular 
matrix. As shown in Figure 6A, Ang-(1-7) also abolished 
the invasion induced by AngII on breast cancer cells.
Vascular endothelial growth factor (VEGF) has 
been identified as a potent cytokine involved in tumor 
angiogenesis and metastasis formation [43]. When breast 
cancer cells were stimulated with AngII, the expression 
of VEGF was increased (2.39 fold). Interestingly, 
cotreatment of Ang-(1-7) with AngII completely abolished 
this increase in VEGF mRNA levels in breast cancer 
cells (Figure 6B). Similar to Ang-(1-7), the treatment 
with an anti-VEGF antibody (bevacizumab) abolished 
Figure 5: Ang-(1-7) blockes AngII induced tumor cell migration. (A) Wound healing assay on MDA-MB231 or LM3 cells. 
Wounds were registered by phase contrast microscopy immediately after scratching (T0) and after 16 h in serum-free medium (T16) 
treated with AngII (10-7M) and/or Ang-(1-7) (10-7M). Bars show results from 3 independent experiments performed and expressed as fold 
increase of wound closure at time 16 hrs (T16) compared to control (untreated cells). Representative pictures of wounds at T0 and T16, 
magnification, 100x. Bars indicate means ± SEM, ***P <0.001 vs control, ###P<0.001 vs AngII. (B) Transwell cell migration assayed with 
MDA-MB231 cells in serum-free media across 8 mm-pore filters coated with type I collagen. The cells that migrated to the lower portion of 
the chamber, were fixed and stained with cristal violet, and five fields per well were counted. Bars indicate number of migrated cells, means 
± SEM, n ≥ 3 ***P <0.001 vs control or ###P<0.001 vs AngII. (C) AngII (10-7M) and Ang-(1-7) (10-7M) had no effect on cell proliferation 
measured over 24 h by cell counting and MTS assay in MDA-MB231 cells.
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AngII –induced cell migration of MDA-MB-231 cells 
(Figure 6D).
Tumor cells are believed to utilize the matrix 
metalloproteases degrading capability to spread to distant 
sites. Previous studies have extensively documented 
AngII-mediated activation of MMP-9 in several cell types 
[44]. In agreement with those studies, we have previously 
demonstrated that AngII, through AT1 receptor, activates 
MMP-9 activity during mammary gland involution [20]. 
As depicted in Figure 6B-6C, Ang-(1-7) abolished MMP-9 
expression and activity triggered by AngII on breast cancer 
cell line MDA-MB231.
DISCUSSION
Our study shows that Ang-(1-7) has the ability to 
counteract AngII-induced metastatic features in breast 
cancer cells. Pro-metastatic effects of AngII in various 
experimental models in vivo and in vitro have been well 
documented and attributed to its actions on the host 
Figure 6: Ang-(1-7) abolishes AngII-induced breast cancer cell invasion, MMP-9 activity and VEGF and MMP-9 
expression. (A) Transwell cell invasion assayed of MDA-MB231 cell in serum-free media across 8 mm-pore filters coated with matrigel. 
Cells that migrated to the lower portion of the chamber were fixed and stained with cristal violet, and five fields per well were counted. 
Bars indicate number of invaded cells, means ± SEM, n ≥ 3, **P <0.01 vs control or #P<0.05 vs AngII. (B) VEGF and MMP-9 mRNA 
expression levels were determined by qRT-PCR on MDA-MB231 cells treated with AngII (10-7M) and/or Ang-(1-7) (10-7M) for 24 h. 
mRNA levels have been normalized to GAPDH and relative to control. Bars indicate means ± SEM, n ≥ 3 ***P <0.001 vs control or ###P 
<0.001 vs AngII. (C) Gelatin-based zymography analysis of MMP-xs9 activity in conditioned medium of MDA-MB231 cells treated as 
in B. Image shown is one representative of 3 independent experiments (Upper panel). For quantification (ImageJ software), results were 
normalized to the quantity of proteins in cell lysate and expressed relative to control (lower panel). Bars indicate means ± SEM, n ≥ 3, 
***P <0.001 vs control or ##P <0.01 vs AngII. (D) Wound healing assay on MDA-MB231 cells. Wounds were registered by phase contrast 
microscopy immediately after scratching (T0) and after 16 h in serum-free medium (T16) treated with AngII (10-7M) and/or bevacizumab 
(100 ug/ml). Bars show results from 3 independent experiments performed and expressed as fold increase of wound closure at time 16 hrs 
(T16) compared to control (untreated cells). Representative pictures of wounds at T0 and T16, magnification 100x. Bars indicate means ± 
SEM, *P <0.05 vs control, #P<0.05 vs AngII.
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microenvironment [31, 32, 45, 46]. Our study confirms 
the reported stimulating effects of AngII on breast cancer 
cell migration, invasion and activation of pro-metastatic 
factors such as MMP-9 and VEGF, supporting the notion 
that AngII can promote tumor cell growth and metastasis 
progression. We show here for the first time that Ang-
(1-7), acting mainly through the Mas receptor, abolishes 
AngII-induced migration, invasion, VEGF expression, 
and MMP-9 activity in breast cancer cells. Moreover, 
we found that Ang-(1-7) completely blockes AngII-
induced EMT, which is an essential step occurring during 
metastasis progression.
Dysregulation of the PI3K/AKT pathway occurs 
in more than 70% of breast cancers [47]. PI3K can be 
activated by RTKs or downstream of GPCRs through 
direct interaction with heterotrimeric G protein subunits 
[48]. In the specific setting of post-lactational regression 
phase, we have previously observed AKT and ERK1/2 
pathway activation in the presence of the AT1 receptor 
blocker Losartan in an in vivo model [20]. Previous 
findings support a dose-dependent effect of AngII on 
cancer cell proliferation and cell survival through the 
PI3K/Akt pathway [27, 28, 44]. In addition, AngII-
mediated cell migration in choriocarcinoma cells can 
be abolished by a selective AT1 antagonist and a PI3K 
inhibitor [49]. In MDA-MB-231 cells, AngII induced 
AKT activation, and pretreatment of cells with PI3K or 
AKT inhibitors significantly reduced AngII-mediated 
cell migration and MMP-2 and-9 upregulation [44]. In 
agreement with these results, we found that AngII induced 
AKT phosphorylation in mammary epithelial cells at 
a very early time point (1 min). In contrast, Ang-(1-7) 
induced AKT phosphorilation at a later time point (15 
min). When both peptides were added together, the pattern 
of activation resembled that of Ang(1-7) blunting the 
early effect of AngII. Moreover, to identify the receptors 
responsible for AngII and Ang-(1-7) mediated AKT 
phosphoryation, we used receptor-type-specific blockers. 
We found that AT1 and Mas receptor, were involved in 
AngII and Ang-(1-7)-mediated AKT phosphorylation, 
respectively. Furthermore, we could demonstrate in 
this study that AngII-induced EMT in non-tumorigenic 
mammary epithelial cell line NMuMG requires AKT 
activation.
Overexpression of AT1 in breast cancer cells 
induces EMT and promotes tumor growth and 
angiogenesis. AT1-overexpressing cells exhibited a 
mesenchymal-like phenotype, together with an increase 
in nuclear accumulation of phospho-Smad3 and Snail, 
increased Smad4 and N-cadherin levels, and a loss in 
E-cadherin [29]. Reduction in Smad4 has been shown 
to suppress TGF-β-induced responses associated with 
EMT in mammary epithelial NMuMG cells in vitro 
[50]. Furthermore, recent studies have reported that AT1 
stimulation by AngII induces EMT via the Smad signaling 
pathway in renal epithelial cells and vascular smooth 
muscle cells in vitro [51, 52]. EMT is often associated 
with aggressive, invasive phenotypes and malignant 
tumor progression [42]. We show here for the first time 
that EMT induced by AngII in mammary epithelial 
cells is partially blocked by Ang-(1-7). Interestingly, the 
concomitant treatment with both angiotensin peptides, 
restored E-cadherin expression. This finding suggests that 
Ang-(1-7) promotes attachment of epithelial cells to the 
extracellular matrix becoming less prone to migrate.
Ang-(1-7) is a natural bioactive peptide of the renin-
angiotensin system produced in many tissues by ACE2 
using AngII as a substrate. It has been shown that Ang-(1-7) 
reduces the growth of human lung tumor xenografts, with a 
concomitant decrease in VEGF and reduced vessel density, 
as well as decreasing the growth of orthotopic human 
estrogen receptor–positive or HER2-overexpressing breast 
tumor xenografts [10, 53, 54]. It has also been recently 
demonstrated that Ang-(1-7) decreases cell growth and 
angiogenesis of human nasopharyngeal carcinoma 
xenografts [55]. However, there are only very few reports 
on Ang-(1-7)’s role in breast cancer development. We 
demonstrate here that in a highly aggressive and metastatic 
breast cancer cell line Ang-(1-7) completely prevented 
AngII-induced cell migration and invasion.
Besides, our study shows that AngII-induced ERK1/2 
activation is inhibited by Ang-(1-7). Several studies have 
shown that activation of ERK1/2 plays an important role 
in cell migration of several tumors [56]. Our studies are 
also in agreement with the previous studies demonstrating 
that Ang-(1-7) decreases the ERK1/2 signal transduction 
pathway in lung and prostate cancer [14, 53]. It is likely 
that Ang-(1-7) activates a signaling pathway that negatively 
regulates AngII-induced ERK1/2 and AKT activation and 
through this mechanism is able to block breast cancer 
migration and invasion induced by AngII. Further studies 
unveiling the exact mechanism through which Ang-(1-7) 
counteracts AngII effects might help to provide a better 
understanding of their role in breast cancer development.
Enzymatic degradation of ECM is one of the crucial 
steps in cancer invasion and metastasis. MMP-9, is the 
main extracellular matrix protein-degrading enzyme 
known to play an important role in breast cancer cell 
migration and invasion [57, 58]. In breast tumor D3H2LN 
cells, AngII upregulates MMP-2 / MMP-9 and ICAM1, 
which are involved in cell adhesion, migration, and 
invasion [59]. In MDA-MB-231 cells, specific blocking 
of MMP-2 and MMP-9 by siRNA significantly suppressed 
AngII-induced cell migration [24, 44]. In this study, we 
found that the enhanced expression and enzymatic activity 
of MMP-9 induced by AngII was significantly abolished 
by Ang-(1-7). Moreover, we also found that Ang-(1-7) 
in breast cancer cells also inhibits AngII-induced 
VEGF expression, a robust stimulator of angiogenesis. 
Notably, VEGF expression is required for the increased 
tumor initiation capacity of breast cancer cells that have 
undergone EMT [43]. These results are in agreement with 
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previous studies showing significant VEGF reduction in 
nasopharyngeal carcinoma cell lines overexpressing Ang-
(1-7) [55]. As we also show in this study that anti-VEGF 
treatment of triple negative breast cancer cells completely 
suppresses AngII-induced migration, our results may also 
indicate the potency of a new strategy, using a combined 
treatment of Ang-(1-7) and anti- VEGF to prevent 
invasion, angiogenesis, and metastasis of aggressive breast 
cancer tumors.
The opposing biological effects of Ang-(1-7) and 
AngII in different scenarios has been vastly demonstrated 
[60]. However, whether Ang-(1-7) had any protective effect 
against breast cancer progression remained unknown. In the 
present study, we explored this possibility and we found 
that Ang-(1-7) reverses EMT, migration, invasion, VEGF, 
and MMP-9 activity induced by AngII. Consequently, 
in our experimental settings, activation of the Ang-(1-7)/
Mas receptor axis acts as a physiological antagonist of the 
AngII/AT1 receptor axis. Therefore, it is worth to evaluate 
in upcoming experiments, whether Ang(1-7) represents a 
better alternative to prevent breast cancer progression than 
the treatment with an AT1 receptor blocker.
MATERIALS AND METHODS
Reagents and antibodies
D-Ala7-Ang-(1-7) (A779), Irbesartan, AngII and 
Ang-(1-7) were purchased from Bachem AG, Bubendorf, 
Switzerland, Losartan from Sigma-Aldrich (St. Louis, 
MO, USA), and PD123319 (PD) from Parke-Davis 
Pharmaceutical Research (Detroit, MI, USA). D-Pro7-
Ang-(1-7) (D-Pro) was manufactured by Biosyntan 
(Berlin, Germany), the monoclonal anti-VEGF antibody, 
bevacizumab, was purchased from Roche, Switzerland), 
antibodies against AKT and pAKT from Cell Signaling 
(Beverly, CA, USA) and against ERK and pERK from 
Santa Cruz Biotechnology Inc. (Santa Cruz CA, USA.). 
The primary antibody for immunofluorescence, anti-E-
cadherin/CDH1 (ECCD-2), was purchased from Zymed 
– Thermo Scientific (Massachusetts, USA), and anti-
fibronectin from Gibco-BRL (Massachusetts, USA). The 
secondary antibodies for immunofluorescence, anti-rat 
Alexa Fluor 568 and anti-rabbit Alexa Fluor 488, came from 
Thermo – Scientific. The other secondary antibodies used 
including horseradish peroxidase (HRP)-conjugated anti-
rabbit and mouse IgG have been delivered by Santa Cruz 
Biotechnology Inc. AKT inhibitor A6730 (Akt1/2 kinase 
inhibitor), phosphatase inhibitor, and protease inhibitor 
cocktail were purchased from Sigma. Oligos for qRT-PCR 
were acquired from Invitrogen (Carlsbad, CA, USA).
Cell culture and treatments
NMuMG cells were grown in Dulbecco’s Modified 
Eagle’s Medium (DMEM high glucose, Invitrogen 
(Massachusetts, USA) supplementary with 10% fetal bovine 
serum; MDA-MB231 cells were grown in RPMI 1640 
supplementary with 10% fetal bovine serum; and LM3 cells, 
derived from mammary adenocarcinoma spontaneously 
occuring in Balb/c mice, were gently provided by Dr. Elisa 
Bal de Kier Joffé, (Roffo Institute, Buenos Aires, Argentina) 
and grown in MEM supplementary with 5% fetal bovine 
serum. All cells were incubated at 37°C in a humidified 
atmosphere of 5% CO
2
. For Wound Healing Migration 
assays, MDA-MB231 and LM3 cells were grown to 
confluence and then starved in serum-free medium during 
8 h before being treated with AngII, Ang-(1-7), or both (10-
7M). For transwell migration and invasion assays, cells were 
starved for 24 in medium supplemented with 1% serum and 
then incubated with AngII, Ang-(1-7) or both 10-6 M in serum 
free medium. For CellTiter 96* Aqueous One Solution Cell 
Proliferation Assay (MTS), zymography, and MMP-9 and 
VEGF expression assays, the AngII/Ang-(1-7) concentration 
was 10-7 M. For Western blot (WB) assays, NMuMG cells 
were starved in serum-free medium for 3 h, and then, cells 
were stimulated at different time points with AngII, Ang-
(1-7), or both at a final concentration of 10-7 M. When treated 
with AT1, AT2, and Mas receptor blockers, cells were pre-
incubated for 5 min with the corresponding antagonists, at 
a final concentration of 10-6 M. For EMT assays, cells were 
starved over-night in 2% serum-supplemented medium, and 
then treated with AngII, Ang-(1-7), or both in a concentration 
of 10-7 M, every 24 h for 3 days. Cells stimulated with TGF-β 
(4 ng/ml; positive control), received treatment every 48 h for 
3 days. In assays in which the AKT inhibitor, A6730, was 
used, its final concentration was 1 μM, and cells were pre-
incubated with it for 1 h.
Quantitative RT-PCR
Quantitative Real-Time PCR was performed as 
previously described [61]. cDNA was synthesized from 
1 μg of total RNA using oligo-dT and reverse transcriptase 
(Reverse Transcriptase MMLV, Promega, Madison, USA) 
as recommended by the manufacturer. PCR amplification 
(35 cycles) was performed on 20 ng cDNA using 
oligonucleotide primers as follows:
- Mouse E-cadherin forward GCTTCAGT 
TCCGAGGTCTACAC, reverse CTGTGATGGTGCC 
GTCTGTC;
- Mouse fibronectin forward TACCAAGG 
TCAATCCACACCCC, reverse CAGATGGCAA 
AAGAAAGCAGAGG;
- Mouse GAPDH forward GAGTCAACG 
GATTTGGTC, reverse CGAAGGTGGAAGAGTGG 
GAGTTG;
- Human GAPDH- forward GAGTCAACG 
GATTTGGTC, reverse TTGATTTTGGAGGGATCTCG;
- Mouse MMP9 forward AGACCTGGGCA 
GATTCCAAACC, reverse GCAAAGGCGTCG 
TCAATCACC;
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- Mouse N-cadherin forward TGGATGAAA 
CGGCGGGATAA, reverse TGTGGCTCAGCATG 
GATAGG;
- Mouse α-SMA forward ACCACCATGT 
ACCCAGGCATT, reverse GCTGGAAGGT 
AGACAGCGAAG;
- Mouse VEGF-F forward GCCCACTGAG 
GAGTCCAACA, reverse GCTGGCCTTGGTGAGGTTT.
Western blot analysis
Cells were solubilized in lysis buffer (30 mM NaCl, 
0.5% TritonX-100, 50 mM Tris–HCl; pH7.4) containing 
a cocktail of phosphatase and protease inhibitors. 
Supernatant was collected (14,000 ×g, 4°C, 20 min), and 
protein concentration was determined with a Bradford 
protein assay kit (Bio-Rad Laboratories, California, 
USA). Equal quantities of protein (25 μg) were subjected 
to SDS-PAGE and transferred onto PVDF membranes 
(GE Healthcare Life Science, Buckinghamshire, UK). The 
membranes were incubated at 4°C overnight with primary 
antibodies ERK1/2 (1:1,000), p-ERK1/2 (1:1,000), AKT 
(1:1,000), pAKT (1:1,000), GAPDH (1:1,000), diluted in 
3% of dry low-fat milk or 3% BSA for phosphorylated 
antibodies, followed by incubation with horseradish 
peroxidase (HRP)-conjugated rabbit or mouse IgG 
(1:5,000). Signal intensity was detected using an Enhanced 
Chemiluminescence Kit (ECL Prime, Amersham, GE 
Healthcare, Buckinghamshire, England) and quantified 
using Syngene G-Box XR5 (Syngene, Maryland, USA).
Zymography
Conditioned medium from MDA-MB-231 cells, 
previously treated for 24 h with AngII, Ang-(1-7), or both 
in serum-free medium, were collected and centrifuged at 
800 rpm for 5 min to remove cellular debris. Samples were 
then subjected to electrophoresis on gelatin substrate gels 
(8.8% SDS-polyacrylamide slab gels containing 1 mg/ml 
gelatin). MMP9 activity was visualized as a clear band at 
90 kDa after Coomassie Blue coloration. The zymograms 
were scanned and subjected to densitometric analyses 
using the PC version of NIH Image J (Scion Corp., 
Frederick, MD, USA).
Immunofluorescence
NMuMG cells were grown on sterile glass cover 
slips in 12-well plates for 4 days and immediately fixed 
with 4% Paraformaldehyde in PBS. After being washed 
2x with PBS, they were incubated for 15 min with a PBS 
+ 0.1% Triton X-100 solution, and then blocked 1 h with 
5% BSA in PBS + Triton X-100 0.025% solution. Then, 
they were washed and incubated with the appropriate 
primary antibodies over-night at 4ºC: anti E-cadherin 
(1:2,000) and anti-fibronectin (1:100) diluted in a 3% 
BSA/PBS-T solution, or vehicle as an isotype control. 
Cells were incubated with specific secondary antibodies: 
Alexa 568 conjugated goat ant-rat or Alexa 488 conjugated 
goat ant-rabbit, diluted (both 1:400) in 3% BSA/PBS-T 
solution. Nuclei were counterstained with 4′,6-diamidino- 
2-fenylindole (DAPI; Sigma Aldrich, St. Louis, MO, USA) 
for 10 min. Sections were finally air-dried and mounted 
with 80% glycerol. Immunofluorescence pictures were 
acquired with Olympus IX-81 fluorescence microscope 
(Tokyo, Japan). ImageJ was used for processing and 
analysis of the signal intensity.
Migration Assays
For wound healing assays with MDA-MB231 or 
LM3 cells, 500,000 cells were grown to confluence in 
6-well plates and, after starvation, cross-shape wounds 
were performed in the monolayer using a sterile 10-μl 
pipette tip. Wounds were scanned by phase contrast 
microscopy immediately after scratching (T0) and after 
16 h in serum-free medium (T16) treated with AngII 
(10-7M) and/or Ang-(1-7) (10-7M) and or bevacizumab 
(100 ug/ml). For wound-closure area quantification, 
3 images per wound were captured, in a total of 2 
wounds per well, at T0 and T16, using a camera (Nikon 
Coolpix P5100; Tokyo, Japan) integrated to a white 
field inverted microscope (Nikon Eclipse TS100). The 
areas were quantified using Image Pro-Plus software 
(Media Cybernetics, Inc. Rockville, MD, USA). For each 
condition, the wound closure was calculated as the ratio of 
wound diameter at T16 relative to T0.
For transwell migration assays, cell motility was 
tested in 8-μm pore polycarbonate membrane transwell 
chambers (Corning Inc, NY, USA). Membranes 
were coated on both sides with 25 μg/ml of rat tail 
collagen I (Roche, Basel, Switzerland). Cells were 
starved in medium (1% serum) for 24 h. For plating 
in transwells, cells were re-suspended in serum-free 
medium and 80,000 cells/250 μl were added to the 
top chamber, with the corresponding angiotensin or 
PBS as negative control. Five hundred μl serum-free 
medium was added to the bottom chamber, except for 
one which contained 10% serum as a positive control 
of migration. Cells were allowed to migrate for 20 h. 
For quantification, non-migrated cells were scraped 
from the top membrane, and migrated cells in the lower 
chamber were fixed in fresh 4% PFA for 20 min and 
stained in 0.1% crystal violet for 30 min. Once washed 
with H
2
O and air dried, pictures were taken, and 
migrated cells were counted in five different random 
fields in duplicate wells using a camera integrated to a 
white field inverted microscope. The number of cells/
field was counted using the ImageJ 1.37v software, and 
results were expressed as the number of treated cells 
capable to migrate per field. The results were expressed 
showing the mean ± SEM.
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Invasion Assay
Invasion was tested in 8-μm pore polycarbonate 
membrane transwell chambers coated with matrigel 
matrix 0.3 mg/ml (Corning, NY, USA) according to 
the manufacturer’s recommendations. For plating in 
transwells, cells were re-suspended in serum-free medium, 
and 1.5 × 105 cells/250 μl were added to the top chamber 
with the corresponding angiotensin or PBS as a negative 
control. Five hundred μl serum-free medium was added to 
the bottom chamber, except for one well which contained 
10% serum as a positive control of invasion. Cells were 
allowed to migrate for 24 h and then proceeded following 
the transwell migration assayed describe above.
Cell viability assay
Cell viability was assessed using the CellTiter 96* 
Aqueous One Solution Cell Proliferation Assay [MTS, 
3-(4,5-dimethylthiazol-2yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium] (Promega, Madison, 
WI, USA). Three thousand MDA-MB231 cells were 
grown in a 96-well plate and starved in medium containing 
2% FBS. After 24 h, cells were stimulated with AngII, 
Ang-(1-7) or both (10-7 M) in serum-free medium. The 
cell proliferation assay was then performed according to 
the manufacturer’s instructions. The quantity of formazan 
product was determined by measuring absorbance at 
450 nm using a microplate sepectophotometer (Glomax 
Multi Detection System, Promega, WI, USA).
Statistical Analysis
Statistical significance of differences was 
determined with One-way ANOVA followed by Tukey 
posttest. Data are as mean ± SEM. A P value of less than 
0.05 was considered statistically significant.
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